Regulatory Roundup: ICH Draft Residual Solvents Guideline Published; And More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: ICH Draft Residual Solvents Guideline Published; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA published this week as a draft recommendation the Step-2 version of the International Conference on Harmonization’s Q3C(R5) Guideline on Residual Solvents to account for new toxicity data related to cumene (Cumol; isopropylbenzene; isopropylbenzol; (1-methyl/ethyl)benzene; 2­Phenylpropane). ICH finalized and approved Q3C(R4), the fourth revision to this guideline, in July 2007. This Step-2 guideline represents a fifth revision, which ICH issued in the form of a final concept paper in June 2009 and approved in March 2010. In Q3C(R4), cumene is listed as a Class-3 solvent in ICH's table of residual solvents. The fifth revision aims to place cumene into Class 2 based on new toxicity data.

 

The Bulk Pharmaceuticals Task Force (BPTF), an affiliate of the Society of Chemical Manufacturers and Affiliates (SOCMA), has released a Quality Agreement template designed for the custom manufacture and release of active pharmaceutical ingredients (APIs). The organization released a general API Quality Agreement Template in May 2010. The templates are meant to help manufacturers, suppliers, and distributors comply with current regulations, including the International Conference on Harmonization Q7 guideline, by putting into place standardized quality agreements.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here